31 results about "Uridine phosphorylase" patented technology

The use of at least one compound of formula I or II or pharmaceutically acceptable salts thereof, for preparing a pharmaceutical composition that acts by inhibiting the phosphorylase uridine enzyme, and the use of the compounds for preparing a pharmaceutical composition that acts by inhibiting the human phosphorylase uridine enzyme, which can be optionally used in combination with at least one antineoplastic, wherein the inhibition increases the effectiveness of antineoplastic and decreases the side effects caused by the administration of antineoplastics.

A fermentation medium comprises: NaCl (3-12 g / L), glucose (10-25 g / L), extract yeast (5-15 g / L), peptone (2-15 g / L), K2HPO4-H2O (1 / 3) (2-5 g / L), uridine (7-25 mmol / L), inosine (15-30 mmol / L) and double distilled water. A fermentation method based on the fermentation medium comprises: streaking, inoculating and culturing lactobacillus brevis for 12-48 h, preserving at 4 DEG C for a standby application; taking and dissolving a certain amount of extract yeast in double distilled water, adjusting pH at 6.0-8.0, disinfecting at 121 DEG C for 15-20 min, and obtaining an activating solution containing 1-10% by mass of extract yeast; picking lactobacillus brevis, inoculating to the activating solution, activating at 30-40 DEG C for 4-12 h, and obtaining activated lactobacillus brevis thalluses; inoculating the lactobacillus brevis thalluses to the fermentation medium with an inoculation volume of 1-10% by volume; fermenting for 4-12 h with a medium temperature of 30-40 DEG C and a shaking-table rotating speed of 90-180 r / min, and obtaining a fermentation liquor; centrifuging the fermentation liquor for 10-30 min with a speed of 3000-5000 r / min, in a centrifuge tube obtaining a deposition which is the fermented whole-cell lactobacillus brevis wet thallus, and taking the fermented whole-cell lactobacillus brevis wet thallus as a uridine phosphorylase source to carry out nucleosides fermentation.

A method for producing cladribine (2-chloro-2′ deoxyadenosine) comprising the steps of: a) reaction of 2-deoxyuridine with 2-chloroadenine, in the presence of uridine phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase) in an aqueous reaction medium possibly containing up to 40% v / v of an aprotic dipolar solvent, to obtain cladribine dissolved in said reaction medium; b) isolation of the cladribine by precipitation by means of concentration and alkalinisation of the reaction medium up to pH 11.5-12.5.